NCT00046748View on ClinicalTrials.gov

Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

484

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions
Asthma
Interventions
DRUG

Omalizumab

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY